Entity

Time filter

Source Type


Fan B.,Dalian Medical University | Zhang L.,Tumor Hospital of Liaoning Province | Li X.-C.,Dalian Medical University | Song X.-S.,Dalian Medical University | Wang J.-B.,Dalian Medical University
National Medical Journal of China | Year: 2013

Objective: To systematically assess the effects of neoadjuvant chemotherapy on the prognostic risk of invasive transitional bladder cancer. Methods: All known randomized controlled trials (RCTs) on neoadjuvant chemotherapy in the treatment of invasive transitional bladder cancer, published from the date of database building to September 2012, were retrieved from such databanks as Pubmed, CBMdisc, Embase and Cochrane. The data on 5-year survival rate of included studies were extracted for further heterogeneity exploration, subgroup analysis and statistical pooling with the RevMan 5.10 software. Results: Fourteen subjects involving 2072 cases and 2086 controls were published from 1991 to 2012. The overall odds ratio of survival suggested a 21% relative reduction in mortality risk for neoadjuvant chemotherapy compared to that on control (OR=0.79, 95% CI: 0.70-0.90). In subgroup analysis according to different neoadjuvant chemotherapies, MCV (methotrexate, cisplatin and vinblastine) and MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapies showed significant benefit to overall survival with 28% and 25% reduction in risk of death respectively (OR=0.72, 95% CI: 0.60-0.86, OR=0.75, 95% CI: 0.59-0.96). However, no significant difference existed in effects between C (cisplatin) chemotherapy, CM (cisplatin and methotrexate) chemotherapy and CD (cisplatin and docetaxel) chemotherapy and controls. In subgroup analysis according to local treatment of cystectomy or radiotherapy after neoadjuvant chemotherapy, the patients with cystectomy showed significant benefits in overall survival with 25% reduction in risk of death (OR=0.75, 95% CI: 0.65-0.87). However, the patients with radiotherapy or radiotherapy plus cystectomy showed no significant benefits in overall survival. Conclusions: MCV and MVAC neoadjuvant chemotherapies improve survival among patients with bladder cancer. And neoadjuvant chemotherapy has better long-term survival after cystectomy. Copyright © 2013 by the Chinese Medical Association.


Wang Z.,Northeastern University China | Yu G.,Northeastern University China | Kang Y.,Northeastern University China | Zhao Y.,Tumor Hospital of Liaoning Province | Qu Q.,Northeastern University China
Neurocomputing | Year: 2014

Breast tumor detection in digital mammography is one of the most important methods of breast cancer prevention. Computer-aided diagnosis (CAD) based on extreme learning machine (ELM) has significant meanings for breast tumor detection as it has good generalization abilities and a high learning efficiency. In this paper, a breast tumor detection algorithm in digital mammography based on ELM is proposed. First, a median filter is used for noise reduction, and contrast enhancement of the digital mammography in data preprocessing. Next, methods of wavelet modulus maxima transform, morphological operation and region growth are used for the breast tumor edge segmentation. Then, five textural features and five morphological features are extracted. Finally, an ELM classifier is used to detect the breast tumor. Comparing breast tumor detection based on Support Vector Machines (SVM), with breast tumor detection based on ELM, not only does ELM have a better classification accuracy than SVM, but it also has a greatly improved training speed. © 2013 Elsevier B.V.


Wang Z.-Q.,Northeastern University China | Kang Y.,Northeastern University China | Yu G.,Northeastern University China | Zhao Y.-J.,Tumor Hospital of Liaoning Province
Dongbei Daxue Xuebao/Journal of Northeastern University | Year: 2013

Breast tumor detection is an effective way for preventing breast cancer, and the classification algorithm of extreme learning machine(ELM) that based on X-Ray image feature model of breast had been used in computer aided detection of breast tumor. Due to the low learning efficiency and detection accuracy of ELM caused by the dependence between features, a breast tumor detction algorithm was proposed in this paper based on features selection ELM. The methods of impact value selection, sequential forward selection and genetic algorithm were used to improve the performance of ELM. The 490 X-Ray images used in the experiment came from Tumor Hospital of Liaoning Province, and the results showed that the precision of breast tumor detection could be improved with the proposed method especially for genetic selection algorithm.


Liu C.,Liaoning Medical University | Cao X.,Shenyang University | Zhang Y.,Liaoning Medical University | Xu H.,Tumor Hospital of Liaoning Province | And 4 more authors.
Molecular Biology Reports | Year: 2012

The aim is to investigate the clinical implications of the Oct-4 and Nestin protein in human breast cancers. A total of 346 cases including 26 fresh and 320 paraffin-embedded tumor tissues were selected for characterizing the frequency of CD44 +CD24 - tumor cells by flow cytometry and the differential expression of the stem cell-related genes between CD44 +CD24 - and non- CD44 +CD24 - tumor cells was analyzed by PCR Array and immunofluorescence. In comparison with the non- CD44 +CD24 - tumor cells, the CD44 +CD24 -, particularly for those with high percentage of Oct-4 + and Nestin +, tumor cells had higher tumorigenicity by forming mammospheres in vitro. More importantly, 42 (13.125%) out of 320 tumor tissues were positive for Oct-4 and Nestin staining. Universal analysis and multivariate analysis revealed that the expression of Oct-4 and Nestin was associated significantly with younger age, pathogenic degrees, lymph node metastasis and triple-negative breast cancer independently (P<0.05) as well as shorter survival (P = 0.001). Oct-4 and Nestin were important regulators of the development of breast cancer, and Oct-4 and Nestin may be used as predictors for the prognosis of breast cancers.©Springer Science+Business Media B.V. 2011.


Xu D.,Shenyang University | Xu H.,Tumor Hospital of Liaoning Province | Ren Y.,Liaoning Medical University | Liu C.,Liaoning Medical University | And 3 more authors.
PLoS ONE | Year: 2012

We investigated the expression status of periostin in breast cancer stem cells and its clinical implications in order to lay a foundation for managing breast cancer. CD44+/CD24-/line- tumor cells (CSC) from clinical specimens were sorted using flow cytometry. Periostin expression status was detected in CSC cells and 1,086 breast cancer specimens by Western blot and immunohistochemistry staining, with the CSC ratio determined by immunofluorescence double staining. The relationship between the periostin protein and clinico-pathological parameters and prognosis was subsequently determined. As a result, CSC cells are more likely to generate new tumors in mice and cell microspheres that are deficient in NOD/SCID compared to the control group. Periostin protein was expressed higher in CSC cells compared to the control cells and was found to be related to CSC chemotherapy resistance. Moreover, periostin expression was found to be related to the CSC ratio in 1,086 breast cancer specimens (P = 0.001). In total, 334 (30.76%) of the 1,086 breast cases showed high periostin expression. After universal and Spearman regression correlation analysis, periostin was observed to be related to histological grade, CSC ratio, lymph node metastasis, tumor size, and triple-negative breast cancer (all P<0.05). Furthermore, periostin was shown to attain a significantly more distant bone metastasis and worse disease-specific survival than those with none or low-expressed periostin protein (P = 0.001). In the Cox regression test, periostin protein was detected as an independent prognostic factor (P = 0.001). In conclusion, periostin was found to be related to the CSC and an independent prognostic factor for breast cancer. It is also perhaps a potential target to breast cancer. © 2012 Xu et al.

Discover hidden collaborations